1
Home
Companies

Lyra Therapeutics

#10212

Rank

$13.67M

Marketcap

US United States

Country

Lyra Therapeutics
Leadership team

Dr. Maria Palasis Ph.D. (CEO, Pres & Director)

Mr. Jason Cavalier (CFO, Treasurer & Sec.)

Mr. R. Donald Elsey MBA (Advisor)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics, Wellness
Number of Employees
50 - 100
Headquarters
Watertown, Massachusetts, United States
Established
2005
Company Registration
SEC CIK number: 0001327273
Revenue
5M - 20M
Traded as
LYRA
Social Media
URL
https://lyratherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
History

Lyra Therapeutics was founded in 2017 with the mission to discover and develop breakthrough therapies for ENT diseases by leveraging innovation in drug delivery combined with an extensive understanding of the biology of the ear, nose and throat. The company has established a leadership position in ENT treatments and therapies and has developed an extensive portfolio of products in the field of ENT, including an injectable treatment for ear infection, several topical treatments for chronic rhinitis, anti-fungal otic drops and a custom-designed prescription medical device.

Mission
Our mission is to be a leader in developing treatments for people with ENT diseases and providing better outcomes for them.
Vision
Our vision is to be the global leader in providing innovative treatments to improve patient outcomes and quality of life in the ENT community.
Key Team

Ms. Corinne Noyes (Sr. VP of Commercial Strategy & Market Devel.)

Mr. Ray Knox (VP of Operations)

Dr. Harlan W. Waksal M.D. (Exec. Chairman)

Dr. Carmichael S. Roberts Jr., Ph.D. (Co-Founder)

Ms. Ellen Cavaleri (Sr. VP of Investor Relations & Communications)

Ms. Vineeta Belanger Ph.D. (Sr. VP of Clinical Affairs)

Dr. Robert Richard Ph.D. (Sr. VP of Technical Operations)

Recognition and Awards
Lyra Therapeutics was awarded an R&D100 Award in 2018 for its innovative product, an injectable treatment for ear infection, as well as an Innovative Drug Delivery Award at the Annual World ENT Congress in 2017.
References

https://in.investing.com/equities/lyra-therapeutics-inc

https://finance.yahoo.com/quote/LYRA/profile?p=LYRA

https://www.crunchbase.com/organization/lyra-therapeutics

https://companiesmarketcap.com/

https://lyratherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Lyra Therapeutics
Leadership team

Dr. Maria Palasis Ph.D. (CEO, Pres & Director)

Mr. Jason Cavalier (CFO, Treasurer & Sec.)

Mr. R. Donald Elsey MBA (Advisor)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics, Wellness
Number of Employees
50 - 100
Headquarters
Watertown, Massachusetts, United States
Established
2005
Company Registration
SEC CIK number: 0001327273
Revenue
5M - 20M
Traded as
LYRA
Social Media
URL
https://lyratherapeutics.com